Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker-Reference-Cited by-同舟云学术

Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker

Published:2004-05-10 Issue:6 Volume:125 Page:729-742
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

McElwaine Suzanne,Mulligan Claire,Groet Jürgen,Spinelli Monica,Rinaldi Andrea,Denyer Gareth,Mensah Afua,Cavani Simona,Baldo Chiara,Dagna-Bricarelli Franca,Hann Ian,Basso Giuseppe,Cotter Finbarr E.,Nizetic Dean

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2004.04982.x/fullpdf

Reference60 articles.

1. Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome;Abe;Human Genetics,1989

2. Natural history of GATA1 mutations in Down Syndrome;Ahmed;Blood,2003

3. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study;Al-Kasim;Journal of Pediatric Hematology/Oncology,2002

4. Down syndrome, transient myeloproliferative syndrome, and leukemia: bridging development and neoplasia;Arceci;Journal of Pediatric Hematology/Oncology,2002

5. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc;Blackwood;Science,1991

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PRAME for acute myeloid leukemia therapy;Frontiers in Immunology;2024-03-26

2. Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study;Cancers;2022-03-21

3. Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view;Expert Reviews in Molecular Medicine;2021

4. Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology;Molecular Therapy - Methods & Clinical Development;2020-12

5. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer;Cell Proliferation;2020-03